TRACON Pharmaceuticals Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRACON Pharmaceuticals stock.
View analyst ratings for TRACON Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given TRACON Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TRACON Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

TRACON Pharmaceuticals saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 560,500 shares, an increase of 56.7% from the January 28th total of 357,800 shares. Based on an average daily trading volume, of 643,700 shares, the days-to-cover ratio is currently 0.9 days. Currently, 4.3% of the company's stock are short sold.
View TRACON Pharmaceuticals' Short Interest.

TRACON Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 12th 2021.
View our earnings forecast for TRACON Pharmaceuticals.

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) issued its quarterly earnings results on Thursday, February, 25th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.34) by $0.03.
View TRACON Pharmaceuticals' earnings history.

TRACON Pharmaceuticals' stock was trading at $1.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TCON stock has increased by 483.0% and is now trading at $8.22.
View which stocks have been most impacted by COVID-19.

2 brokerages have issued twelve-month price targets for TRACON Pharmaceuticals' shares. Their forecasts range from $12.00 to $24.00. On average, they anticipate TRACON Pharmaceuticals' share price to reach $18.00 in the next year. This suggests a possible upside of 119.0% from the stock's current price.
View analysts' price targets for TRACON Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to TRACON Pharmaceuticals include Fusion Pharmaceuticals (FUSN), Harpoon Therapeutics (HARP), AVROBIO (AVRO), Cellular Biomedicine Group (CBMG), Opthea (OPT), Cardiff Oncology (CRDF), Innate Pharma (IPHYF), Freeline Therapeutics (FRLN), Innate Pharma (IPHA), SQZ Biotechnologies (SQZ), Aptose Biosciences (APTO), Codiak BioSciences (CDAK), Autolus Therapeutics (AUTL), Outlook Therapeutics (OTLK) and Surface Oncology (SURF).
View all of TCON's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

(TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

TRACON Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Ikarian Capital LLC (19.85%), Opaleye Management Inc. (18.40%), BlackRock Inc. (2.38%), Renaissance Technologies LLC (1.24%), Bank of New York Mellon Corp (0.46%) and GSA Capital Partners LLP (0.34%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc and Saundra L Pelletier.
View institutional ownership trends for TRACON Pharmaceuticals.

TCON stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Jane Street Group LLC, and Vigilare Wealth Management.
View insider buying and selling activity for TRACON Pharmaceuticals or view top insider-selling stocks.

TCON stock was bought by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Opaleye Management Inc., BlackRock Inc., Renaissance Technologies LLC, Bank of New York Mellon Corp, Price T Rowe Associates Inc. MD, and Wells Fargo & Company MN. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, and Saundra L Pelletier.
View insider buying and selling activity for TRACON Pharmaceuticals or or view top insider-buying stocks.

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TCON stock can currently be purchased for approximately $8.22.

TRACON Pharmaceuticals has a market capitalization of $127.24 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-22,670,000.00 in net income (profit) each year or ($7.47) on an earnings per share basis.

TRACON Pharmaceuticals employs 19 workers across the globe.

The official website for TRACON Pharmaceuticals is www.traconpharma.com.

TRACON Pharmaceuticals is headquartered at 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122.

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]